US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Biogen Inc.

BIIBNASDAQ

197.78

USD
-2.84
(-1.42%)
Market Closed
14.48P/E
13Forward P/E
0.72P/E to S&P500
28.700BMarket CAP
- -Div Yield
Upcoming Earnings
18 Oct-24 Oct
Shares Short
8/31/22
1.89M
Short % of Float
1.47%
Short % of Shares Outs.
1.30%
% Held by Insiders
0.69%
% Held by Institutions
86.46%
Beta
0.42
PEG Ratio
-1.99
52w. high/low
291.54/187.16
Avg. Daily Volume
0.93M
Return %
Stock
S&P 500
1 year
(32.09)
(16.94)
3 years
(17.01)
23.82
5 years
(37.28)
47.73
Scale: |
High
Low
84.75
42.86
73.59
37.21
55.34
41.75
68.60
45.96
120.66
64.28
157.18
111.44
298.82
139.72
361.93
270.62
480.18
254.00
333.65
223.02
348.84
244.28
388.67
249.17
344.00
215.78
374.99
223.25
468.55
221.72
249.00
187.16
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
5.53
10.04
14.02
15.23
18.69
20.83
23.18
29.26
41.05
46.66
52.42
57.73
65.66
76.85
83.56
68.25
72.20
Earnings per share
0.64
2.02
2.68
3.38
3.98
5.09
5.80
7.86
12.42
15.37
16.95
11.94
21.62
31.47
24.86
9.67
13.98
FCF per share
1.90
2.33
4.41
3.16
5.75
6.09
6.80
(4.91)
11.23
13.32
17.38
12.17
25.87
34.25
22.86
20.79
15.53
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
0.59
0.90
0.94
0.58
0.69
1.04
1.10
14.81
1.22
2.79
3.33
9.23
4.32
3.58
3.43
1.83
0.63
Book Value per sh.
21.12
17.52
19.86
21.65
21.39
26.51
29.26
36.38
45.73
40.63
55.59
59.33
63.64
71.32
66.50
67.72
75.44
Comm.Shares outs.
339
316
292
287
252
242
238
237
236
231
218
213
205
187
161
161
147
Avg. annual P/E ratio
71.8
28.3
20.7
14.4
14.1
18.2
23.5
27.6
25.5
22.8
16.6
24.5
14.5
8.4
11.7
30.1
14.5
P/E to S&P500
4.0
1.6
1.0
0.2
0.7
1.1
1.6
1.6
1.4
1.1
0.7
1.0
0.6
0.3
0.3
1.0
0.7
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
1,872
3,172
4,098
4,377
4,716
5,049
5,516
6,932
9,703
10,764
11,449
12,274
13,453
14,378
13,445
10,982
10,634
Operating margin
23.5%
24.6%
29.6%
29.6%
26.5%
34.2%
33.6%
36.3%
40.9%
45.4%
45.0%
43.5%
43.8%
49.0%
33.8%
25.9%
28.2%
Depreciation (m)
376
380
462
428
354
359
366
532
688
600
683
1,081
1,017
681
457
488
546
Net profit (m)
218
638
783
970
1,005
1,234
1,380
1,862
2,935
3,547
3,703
2,539
4,431
5,889
4,001
1,556
2,059
Income tax rate
56.6%
29.9%
31.8%
26.7%
26.9%
26.0%
25.4%
24.2%
25.1%
24.4%
25.1%
47.9%
24.2%
16.3%
19.7%
3.0%
38.4%
Net profit margin
11.6%
20.1%
19.1%
22.2%
21.3%
24.5%
25.0%
26.9%
30.2%
33.0%
32.3%
20.7%
32.9%
41.0%
29.8%
14.2%
19.5%
Working capital (m)
1,130
179
1,535
1,766
1,490
2,063
1,587
1,427
2,453
4,123
5,312
4,505
4,346
3,518
3,145
3,558
4,723
Long-term debt (m)
97
52
1,085
1,080
1,066
1,061
687
592
582
6,522
6,513
5,935
5,937
4,459
7,828
6,604
6,552
Equity (m)
7,150
5,534
5,806
6,222
5,397
6,425
6,962
8,620
10,809
9,373
12,140
12,613
13,040
13,343
10,700
10,896
11,873
ROIC
2.7%
10.4%
10.8%
12.8%
14.3%
15.6%
16.6%
18.7%
24.5%
21.5%
20.0%
13.5%
20.9%
27.1%
20.1%
9.3%
8.0%
Return on capital
5.8%
11.0%
14.2%
16.0%
17.1%
18.9%
18.6%
21.0%
27.6%
24.6%
22.7%
22.2%
23.9%
26.6%
21.2%
7.8%
10.4%
Return on equity
3.0%
11.5%
13.5%
15.6%
18.6%
19.2%
19.8%
21.6%
27.2%
37.8%
30.5%
20.1%
34.0%
44.1%
37.4%
14.3%
17.3%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
27.0%
339.7%
43.5%
77.4%
130.5%
12.4%
60.8%
(34.4)%
33.4%
162.7%
26.4%
52.8%
82.1%
91.6%
181.6%
53.8%
54.7%
Capital Structure
20 Jul · 2022 | Q2
All numbers in millions
Total liabilities
$ 12,050
Total assets
$ 25,081
Long-term debt
$ 6,552
Cash and equiv.
$ 2,647
Goodwill
$ 5,750
Retained earnings
$ 15,274
Common stock
147
Enterprise Value
$ 32,605
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
4,476
2,610
3,803
Receivables
2,471
2,327
1,962
Inventory
804
1,069
1,352
Other
631
(701)
89
Current assets
8,382
6,887
7,857
Acc. Payable
531
455
589
Debt due
1,496
- -
999
Other
2,837
3,287
2,710
Current liabilities
4,864
3,742
4,298
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(18.32)%
(2.08)%
9.09%
Cash flow
(9.05)%
18.52%
(46.49)%
Earnings
(61.10)%
3.56%
11.18%
Dividends
- -
- -
- -
Book value
1.83%
(3.07)%
6.34%
Insider Trading
Type
Shares
Date
Mcdonnell Michael R
Other
3,298
09/01/22
Mcdonnell Michael R
Exempt
2,064
09/01/22
Mcdonnell Michael R
Exempt
2,682
09/01/22
Mcdonnell Michael R
InKind
1,056
09/01/22
Mcdonnell Michael R
Exempt
2,064
09/01/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
3,534
3,682
3,376
2,853
13,445
2021
2,694
2,775
2,779
2,734
10,982
2022
2,532
2,589
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
8.70
9.58
4.36
2.22
24.86
2021
2.55
2.79
2.05
2.29
9.67
2022
2.07
7.19
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Michel Vounatsos
Full-time employees:
9,610
City:
Cambridge
Address:
225 Binney St
IPO:
Sep 17, 1991
Website:
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Recent News
· 3 May, 2022 · The Wall Street Journal
· 7 Apr, 2022 · The Wall Street Journal
· 14 Mar, 2022 · The Wall Street Journal
· 20 Dec, 2021 · The Wall Street Journal
· 9 Nov, 2021 · The Wall Street Journal
· 20 Oct, 2021 · The Wall Street Journal
· 21 Sep, 2021 · The Wall Street Journal
· 12 Aug, 2021 · The Wall Street Journal
· 22 Jul, 2021 · The Wall Street Journal
· 8 Jul, 2021 · The Wall Street Journal
· 7 Jun, 2021 · The Wall Street Journal
· 29 Jan, 2021 · The Wall Street Journal